Xerecept corticorelin: Phase I/II data

Data from 14 evaluable pediatric patients in an open-label, U.S. Phase I/II trial showed that twice-daily subcutaneous Xerecept reduced daily dexamethasone dosing requirements by >50% in 10 patients, ...